Robert W. Baird Initiates Coverage on Dyne Therapeutics (NASDAQ:DYN)

Robert W. Baird assumed coverage on shares of Dyne Therapeutics (NASDAQ:DYN) in a research report report published on Friday morning, Marketbeat reports. The firm issued an outperform rating and a $46.00 price objective on the stock.

Other analysts also recently issued reports about the stock. Royal Bank of Canada began coverage on shares of Dyne Therapeutics in a report on Tuesday, November 26th. They set an “outperform” rating and a $45.00 price objective for the company. Stifel Nicolaus upped their price objective on Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Guggenheim increased their price objective on Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, August 15th. Oppenheimer restated an “outperform” rating and issued a $55.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. cut shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $43.00 to $35.00 in a research report on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $50.42.

Dyne Therapeutics Trading Up 0.5 %

Shares of DYN opened at $25.73 on Friday. Dyne Therapeutics has a 12-month low of $11.51 and a 12-month high of $47.45. The company has a market cap of $2.62 billion, a PE ratio of -7.23 and a beta of 1.09. The stock has a 50-day moving average price of $30.39 and a 200-day moving average price of $35.26.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). As a group, analysts predict that Dyne Therapeutics will post -3.45 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Carlo Incerti sold 16,500 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $28.73, for a total transaction of $474,045.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Oxana Beskrovnaya sold 2,334 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $65,632.08. Following the completion of the sale, the insider now directly owns 201,685 shares of the company’s stock, valued at $5,671,382.20. The trade was a 1.14 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 180,046 shares of company stock valued at $6,300,265 in the last quarter. Insiders own 20.77% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Nisa Investment Advisors LLC lifted its stake in shares of Dyne Therapeutics by 904.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after purchasing an additional 669 shares during the period. Quantbot Technologies LP bought a new position in Dyne Therapeutics in the third quarter worth $34,000. Point72 DIFC Ltd purchased a new position in Dyne Therapeutics during the third quarter valued at $36,000. US Bancorp DE boosted its holdings in shares of Dyne Therapeutics by 776.9% during the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after buying an additional 1,212 shares in the last quarter. Finally, Values First Advisors Inc. bought a new stake in shares of Dyne Therapeutics during the 3rd quarter valued at $62,000. 96.68% of the stock is owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.